Zacks Investment Research
06 Aug 2026, 14:51 UTC · 6w ago
Verdict
Headline leans bearish. We score CGON −0.80 across three claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−0.80strongly bearish
What the story claims
3 claims · scored −1 bearish … +1 bullish
CG Oncology reported quarterly revenues of $1.16 million, missing the Zacks Consensus Estimate by 59.02%.
So whatA significant revenue miss of nearly 60% typically indicates weaker-than-expected commercial traction or operational headwinds.
More negative than 95% of claims this week
CG Oncology reported a quarterly loss of $0.90 per share, exceeding the estimated loss of $0.70 per share.
Continue reading
5 related stories
More negative than 86% of ticker scores this week
Scored by the NIS engine · methodology.
More negative than 86% of claims this week
CG Oncology has only surpassed consensus EPS estimates once over the last four quarters.
So whatA consistent pattern of missing earnings estimates undermines investor confidence in management's guidance.
More negative than 78% of claims this week
Which stocks this story touches
More negative than 86% of ticker scores this week
The company reported a larger than expected quarterly loss and missed revenue estimates significantly.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
+7.3%
Price is moving against the score
$77.74 vs $72.42 close before publication (Aug 5) · not market-adjusted
CGON chart →
